Express Mail No.: EV 871029106 US Page 1 of 2 Attorney Docket No.: 21534-002 CIP NATL Date of Deposit: November 13, 2008

10/540,635 Nodified Form 1449/PTO **Application Number Filing Date** December 12, 2005 NOV 1 3 2008 INFORMATION DISCLOSURE **First Named Inventor** Haines STATEMENT BY APPLICANT Group Art Unit 4161 **Examiner Name** Sean M. Basquill 21534-002 CIP NATL Attorney Docket Number **U.S. PATENT DOCUMENTS** Filing Date If Appropriate U.S. Patent Document No. Exam Cite Sub Class **Issue Date** Name of Patentee(s) or Applicant(s) Class Ño. Initials \*A1 4,879,312 11/07/89 Kamarei et al. 514 560 \*A2 5,569,585 10/29/96 435 6 Goodwin et al. \*A3 6,103,756 08/15/00 Gorsek 514 458 U.S. PUBLISHED APPLICATION DOCUMENTS 地位。 Cite No. Exam U.S. Published Published Name of Patentee(s) or Applicant(s) Class Sub Filing Date Initials Application No. Date Class lf Appropriate \*A4 01/03/02 174 2002/0002154 A1 Guivarc'h et al. 514 \*A5 2002/0110604 A1 08/15/02 Babish, et al. 424 725 FOREIGN PATENT DOCUMENTS 20 k: , 4. 20 Cite No. Date of Publication Translation Exam **Foreign Patent Document** 

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
mitiais		
	*C1	Baek, et al., "The Effects of Two New Antagonists of Secretory PLA₂ on TNF, iNOS, and COX-2 Expression in Activated Macrophages", SHOCK, 12(6):473-478 (1999).
	*C2	Beauregard, et al., "Induction of Nitric Oxide Synthase and Over-Production of Nitric Oxide by Interleukin-1ß in Cultured Lacrimal Gland Acinar Cells", Exp. Eye Res., 77(1):109-114 (2003).
	*C3	Chen, et al., "A 3D-QSAR Study on Ginkgolides and Their Analogues with Comparative Molecular Field Analysis" Bioorg. Med. Chem. Lett., 8(11):1291-1296 (1998).
	*C4	Fan, et al., "Does Astaxanthin Protect Haematococcus Against Light Damage?", Z. Naturforsch., C53, pp. 93-100 (1998).
	*C5	Fies, et al., "Ginkgo Extract in Impaired Vision—Treatment with Special Extract EGb 761 of Impaired Vision Due to Dry Senile Macular Degeneration", Wien. Med. Wochenschr., 152(15/16):423-426 (2002).
	*C6	Guex-Crosier, "Non-Steroidal Anti-Inflammatory Drugs and Ocular Inflammation", Klin. Monatsbl. Augenheilkd., 218(5):305-308 (2001).
	*C7	Jyonouchi, et al., "Immunomodulating Actions of Carotenoids: Enhancement of In Vitro Antibody Production to T-Dependent Antigens", <i>Nutr. Cancer</i> , 21(1):47-58 (1994).
	*C8	Jyonouchi, et al., "Effects of Various Carotenoids on Cloned, Effector-Stage T-Helper Cell Activity", <i>Nutr. Cancer</i> , 26(3):313-324 (1996).
	*C9	Kurashige, et al., "Inhibition of Oxidative Injury of Biological Membranes by Astaxanthin", <i>Physiol. Chem. Phys. &amp; Med. NMR</i> , 22(1):27-38 (1990).

Name of Patentee(s) or Applicant(s)

11/15/01

06/20/90

Abstract

only

Haines, et al.

Haines, et al.

Initials

Office

wo

JΡ

\*B1

\*B2

Number

01/85206 A2

01-156923 A

Express Mail No.: EV 871029106 US Date of Deposit: November 13, 2008

Page 2 of 2 Attorney Docket No.: 21534-002 CIP NATL

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C10	Li, et al., "The Bioavailability of Ginkgolides in Ginkgo Biloba Extracts", Planta Medica, 63(6):563-565 (1997).
	*C11	Lobefalo, et al., "Dry Eye in Allergic Conjunctivitis: Role of Inflammatory Infiltrate", Int. J. Immunopathol. Pharmacol., 12(3):133-137 (1999).
	*C12	Morrow, et al., "Increase in Circulating Products of Lipid Peroxidation (F <sub>2</sub> -Isoprostanes) in Smokers", N.E.J. Med., 332:1198-1203 (1995).
	*C13	Newsholme, et al., "Camp-Specific Phosphodiesterase Inhibitor, Rolipram, Reduces Eosinophil Infiltration Evoked by Leukotrienes or by Histamine in Guinea Pig Conjunctiva", <i>Inflammation</i> , 17(1):25-31 (1993).
	*C14	Okai, et al., "Possible Immunomodulating Activities of Carotenoids in In Vitro Cell Culture Experiments", Int. J. Immunopharmac., 18(12):753-758 (1996).
	*C15	Saponara, et al., "Inhibition of cAMP-Phosphodiesterase by Biflavones of Ginkgo Biloba in Rat Adipose Tissue", J. Nat. Prod., 61(11):1386-1387 (1998).
	*C16	Shaban, et al., "Phosphatidylglycerol Potently Protects Human Retinal Pigment Epithelial Cells Against Apoptosis Induced by A2E, a Compound Suspected to Cause Age-Related Macula Degeneration", <i>Exp. Eye Res.</i> , 75(1):99-108 (2002).
	*C17	Vint, et al., "The Gold Anti-Rheumatic Drug Auranofin Governs T Cell Activation by Enhancing Oxygen Free Radical Production", Eur. J. Immunol., 24(9):1961-1965 (1994).
	*C18	Vint, et al., "The Interaction of Auranofin and Buthionine Sulfoximine Blocks Activation of Human Peripheral T Lymphocytes", Cell. Immunol., 152(1):152-161 (1993).
	*C19	Vint, et al., "The Effects of Auranofin on Activation and Interleukin-2 Release from Human Peripheral Blood Mononuclear Cells", Agents and Actions, 40(3/4):209-214 (1993).
	*C20	Wang, et al., "Astaxanthin-Rich Algal Meal and Vitamin C Inhibit Helicobacter Pylori Infection in BALB/cA Mice", Antimicrobial Agents and Chemotherapy, 44(9):2452-2457 (2000).

<sup>\*</sup> a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior applications, Serial No.10/621,802, filed July 16, 2003, and Serial No. 10/345,856, filed January 16, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications)

Examiner Signature		Date Considered		
-----------------------	--	--------------------	--	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4472559v.1

Express Mail No.: EV 871029106 US Date of Deposit: November 13, 2008

1 VON

Page 1 of 2 Attorney Docket No.: 21534-002 CIP NATL

Middlifed Form 1449/PTO  INFORMATION DISCLOSURE							Application Number 10/540,635						
							Filing Date	December 12, 2005					
							First Named Inventor	Haines					
STATEMENT BY APPLICANT						Group Art Unit 4161					<u> </u>		
The state of the s			•				Examiner Name	S	Sean M. Basquill				
				Attorney Docket Number	21534-002 CIP NATL								
						Ű.s	PATENTIDOCUMENTS			100		Section 15.	
Exam Initials	nitials No. Document No. 18  *A1 4,879,312 1		Issu	e Date	Name	of Patentee(s) or Applicant(s)	C	ass	Sub Class		Filing Date If Appropriate		
			,312	11/07/89 10/29/96		Kamarei et al. ' Goodwin et al.		514 435		560			
			,585							6			
	*A3	6,103	,756	08/1	5/00	Gorse	ek	51	4	458			
							SHED APPLICATION DOCUMENTS		17				
Exam initials	Cite No.		I.S. Published		Publi Da	shed ite	Name of Patentee(s) or Applicant(s)		Class	Sub Class		Filing Dat If Appropria	
	*A4	200	2/0002154	41	01/03	3/02	Guivarc'h et al.		514	174		<del>дрргорна</del>	
	*A5		2/0110604 /	<b>A1</b>	08/15	5/02	Babish, et al.		424	725			
						FORE	GN PATENT DOCUMENTS						
Exam nitials	Cite No.	Foreign Patent Document Name of Office Number					of Patentee(s) or Applicant(s)		te of blication	1	Tran: Yes	slation No	
	*B1	WO 01/85206 A2		A2	A2 Haines		, et al.	11/15/01					
	*B2	JP 01-156923 A			Haines	et al.	06.	/20/90		Abstra	ct		

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C1	Baek, et al., "The Effects of Two New Antagonists of Secretory PLA <sub>2</sub> on TNF, iNOS, and COX-2 Expression in Activated Macrophages", SHOCK, 12(6):473-478 (1999).
	*C2	Beauregard, et al., "Induction of Nitric Oxide Synthase and Over-Production of Nitric Oxide by Interleukin-1ß in Cultured Lacrimal Gland Acinar Cells", Exp. Eye Res., 77(1):109-114 (2003).
	*C3	Chen, et al., "A 3D-QSAR Study on Ginkgolides and Their Analogues with Comparative Molecular Field Analysis". Bioorg. Med. Chem. Lett., 8(11):1291-1296 (1998).
	*C4	Fan, et al., "Does Astaxanthin Protect Haematococcus Against Light Damage?", Z. Naturforsch., C53, pp. 93-100 (1998).
·	*C5	Fies, et al., "Ginkgo Extract in Impaired Vision—Treatment with Special Extract EGb 761 of Impaired Vision Due to Dry Senile Macular Degeneration", Wien. Med. Wochenschr., 152(15/16):423-426 (2002).
	*C6	Guex-Crosier, "Non-Steroidal Anti-Inflammatory Drugs and Ocular Inflammation", Klin. Monatsbl. Augenheilkd., 218(5):305-308 (2001).
	*C7	Jyonouchi, et al., "Immunomodulating Actions of Carotenoids: Enhancement of In Vitro Antibody Production to T-Dependent Antigens", <i>Nutr. Cancer</i> , 21(1):47-58 (1994).
	*C8	Jyonouchi, et al., "Effects of Various Carotenoids on Cloned, Effector-Stage T-Helper Cell Activity", <i>Nutr. Cancer</i> , 26(3):313-324 (1996).
	*C9	Kurashige, et al., "Inhibition of Oxidative Injury of Biological Membranes by Astaxanthin", <i>Physiol. Chem. Phys. &amp; Med. NMR</i> , 22(1):27-38 (1990).

Express Mail No.: EV 871029106 US Date of Deposit: November 13, 2008

Page 2 of 2 Attorney Docket No.: 21534-002 CIP NATL

		THER PRIOR ART ANONIPATIENT LITERATURE DOCUMENTS:
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C10	Li, et al., "The Bioavailability of Ginkgolides in Ginkgo Biloba Extracts", Planta Medica, 63(6):563-565 (1997).
	*C11	Lobefalo, et al., "Dry Eye in Allergic Conjunctivitis: Role of Inflammatory Infiltrate", Int. J. Immunopathol. Pharmacol., 12(3):133-137 (1999).
	*C12	Morrow, et al., "Increase in Circulating Products of Lipid Peroxidation (F <sub>2</sub> -Isoprostanes) in Smokers", N.E.J. Med., 332:1198-1203 (1995).
	*C13	Newsholme, et al., "Camp-Specific Phosphodiesterase Inhibitor, Rolipram, Reduces Eosinophil Infiltration Evoked by Leukotrienes or by Histamine in Guinea Pig Conjunctiva", <i>Inflammation</i> , 17(1):25-31 (1993).
	*C14	Okai, et al., "Possible Immunomodulating Activities of Carotenoids in In Vitro Cell Culture Experiments", Int. J. Immunopharmac., 18(12):753-758 (1996).
	*C15	Saponara, et al., "Inhibition of cAMP-Phosphodiesterase by Biflavones of Ginkgo Biloba in Rat Adipose Tissue", J. Nat. Prod., 61(11):1386-1387 (1998).
	*C16	Shaban, et al., "Phosphatidylglycerol Potently Protects Human Retinal Pigment Epithelial Cells Against Apoptosis Induced by A2E, a Compound Suspected to Cause Age-Related Macula Degeneration", <i>Exp. Eye Res.</i> , 75(1):99-108 (2002).
	*C17	Vint, et al., "The Gold Anti-Rheumatic Drug Auranofin Governs T Cell Activation by Enhancing Oxygen Free Radical Production", Eur. J. Immunol., 24(9):1961-1965 (1994).
	*C18	Vint, et al., "The Interaction of Auranofin and Buthionine Sulfoximine Blocks Activation of Human Peripheral T Lymphocytes", Cell. Immunol., 152(1):152-161 (1993).
	*C19	Vint, et al., "The Effects of Auranofin on Activation and Interleukin-2 Release from Human Peripheral Blood Mononuclear Cells", Agents and Actions, 40(3/4):209-214 (1993).
	*C20	Wang, et al., "Astaxanthin-Rich Algal Meal and Vitamin C Inhibit Helicobacter Pylori Infection in BALB/cA Mice", Antimicrobial Agents and Chemotherapy, 44(9):2452-2457 (2000).

<sup>\*</sup> a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior applications, Serial No.10/621,802, filed July 16, 2003, and Serial No. 10/345,856, filed January 16, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4472559v.1